Booking 6 Systems in Q4, PacBio Begins C2 Upgrades, Will Focus on Niche Applications | GenomeWeb

By Monica Heger

This story was originally published Feb. 9.

Pacific Biosciences booked six new RS instruments in the fourth quarter of 2011— one fewer than it booked in the third quarter — and installed 17 systems, company officials said last week during a conference call to discuss the company's fourth-quarter and full-year earnings.

The company has a current backlog of 16 systems, representing $11 million in revenue, and has a total of 48 systems installed, officials said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.